Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Core Insights - Minerva Neurosciences, Inc. is set to initiate a confirmatory Phase 3 trial for roluperidone targeting negative symptoms of schizophrenia in Q2 2026, with topline data expected in the second half of 2027 [1][9] Business Updates - The company secured $80 million in gross proceeds from a private placement on October 23, 2025, with potential additional funding of up to $120 million contingent on the exercise of warrants [3][4] - Minerva has achieved alignment with the FDA regarding the trial design for the Phase 3 study of roluperidone, which aims to evaluate its efficacy against placebo in approximately 380 patients over a 12-week period [4][9] Financial Results - For Q4 2025, Minerva reported a net loss of $283.7 million, or $25.51 per share, compared to a net loss of $4.3 million, or $0.56 per share, in Q4 2024 [17][28] - Total liabilities increased to $233.8 million as of December 31, 2025, up from $62.8 million in 2024, primarily due to the issuance of convertible preferred stock and warrants [16][27] - Cash and cash equivalents rose to approximately $82.4 million at the end of 2025, compared to $21.5 million at the end of 2024, largely due to the recent financing [19]